Table 2.
Ongoing trials evaluating the safety and efficacy of tralokinumab and lebrikizumab for atopic dermatitis treatment.
| Drug, sponsor | Clinical trial | Phase | Estimated enrolment (number of participants) | Status | Estimated study completion date |
|---|---|---|---|---|---|
| Lebrikizumab, Eli Lilly and Company | NCT04392154 | III | 900 | Recruiting | May 30, 2024 |
| Lebrikizumab, Eli Lilly and Company | NCT04626297 | III | 240 | Not yet recruiting | November 5, 2021 |
| Lebrikizumab, Eli Lilly and Company | NCT04250350 | III | 200 | Recruiting | May 31, 2022 |
| Lebrikizumab, Eli Lilly and Company | NCT04146363 | III | 400 | Recruiting | May 9, 2022 |
| Lebrikizumab, Eli Lilly and Company | NCT04250337 | III | 225 | Recruiting | October 13, 2021 |
| Tralokinumab | NCT04556461 | II | 16 | Recruiting | March 2022 |
| Tralokinumab, LEO Pharma | NCT03587805 | III | 1125 | Enrolling by invitation | September 13, 2021 |
| Tralokinumab, LEO Pharma | NCT04587453 | III | 100 | Recruiting | September 2021 |
| Tralokinumab, LEO Pharma | NCT03556592 | I | 40 | Completed | |
| Tralokinumab, LEO Pharma | NCT03526861 | III | 299 | Active, not recruiting | February 20, 2021 |